Cell Therapeutics (CTIC) agrees to buy the worldwide rights to Pacritinib from S*Bio for $15M in cash and $15M in preferred stock. Shares +6.1% premarket.
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs